Moleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AML

RTTNews | 13 days ago
Moleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AML

(RTTNews) - Pharmaceutical company Moleculin Biotech, Inc. (MBRX) announced Thursday that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of Acute Myeloid Leukemia (AML).

Annamycin is the Company's next-generation anthracycline that has been designed to be non-cardiotoxic (unlike currently prescribed anthracyclines) and has shown to be non-cardiotoxic in the 82 subjects treated in multiple studies in the U.S. and in Europe.

Annamycin is currently in development for the treatment for AML and STS lung mets, and the Company believes the drug may have the potential to treat additional indications.

Annamycin currently has Fast Track Status and Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of relapsed or refractory AML, in addition to Orphan Drug Designation for the treatment of STS lung mets.

read more
Fed Leaves Rates Unchanged Amid Lack Of Progress On Inflation

Fed Leaves Rates Unchanged Amid Lack Of Progress On Inflation

Citing a lack of further progress toward its 2 percent inflation objective in recent months, the Federal Reserve on Wednesday announced its widely expected decision to leave interest rates unchanged. Members of the Fed also reiterated they need "greater confidence" inflation is moving sustainably toward 2 percent before they consider cutting interest rates.
RTTNews | 4h 13min ago
U.K. Market Ends Modestly Lower

U.K. Market Ends Modestly Lower

European markets were mostly closed on Wednesday for Labor Day holiday. Markets in the U.K. and Denmark, which were open for trading, ended the session on a weak note.
RTTNews | 5h 51min ago
Canadian Market Modestly Lower At Noon; Energy, Cannabis Stocks Fall

Canadian Market Modestly Lower At Noon; Energy, Cannabis Stocks Fall

The Canadian market is slightly weak around noon on Wednesday, weighed down by losses in healthcare, energy and consumer discretionary sectors. The mood is cautious with investors digesting the latest batch of economic data from the U.S. and awaiting the Federal Reserve's monetary policy announcement.
RTTNews | 6h 23min ago
U.S. Construction Spending Unexpectedly Edges Slightly Lower In March

U.S. Construction Spending Unexpectedly Edges Slightly Lower In March

Reflecting a decrease in spending on private construction, the Commerce Department released a report on Wednesday showing U.S. construction spending unexpectedly edged slightly lower in the month of March. The report said construction spending dipped by 0.2 percent to an annual rate of $2.084 trillion in March, while economists had expected construction spending to rise by 0.3 percent.
RTTNews | 7h 46min ago
U.S. Manufacturing Index Indicates Modest Contraction In April

U.S. Manufacturing Index Indicates Modest Contraction In April

The Institute for Supply Management released a report on Wednesday showing a modest contraction by U.S. manufacturing activity in the month of April. The ISM said its manufacturing PMI slipped to 49.2 in April from 50.3 in March, with a reading below 50 indicating contraction. Economists had expected the index to edge down to 50.0.
RTTNews | 7h 50min ago
U.S. Crude Oil Inventories Unexpectedly Rebound

U.S. Crude Oil Inventories Unexpectedly Rebound

The Energy Information Administration released a report on Wednesday showing an unexpected rebound by U.S. crude oil inventories in the week ended April 26th. The report said crude oil inventories jumped by 7.3 million barrels last week after tumbling by 6.4 million barrels in the previous week. Economists had expected crude oil inventories to decrease by 2.3 million barrels.
RTTNews | 7h 56min ago